Shang-Wen Chen1, Chien-Yu Lin, Cheng-Man Ho, Ya-Sian Chang, Shu-Fen Yang, Chia-Hung Kao, Jan-Gowth Chang. 1. From the *Department of Radiation Oncology, China Medical University Hospital; †College of Medicine, China Medical University, Taichung; ‡College of Medicine, Taipei Medical University, Taipei; §Graduate Institute of Clinical Medical Sciences, China Medical University; ║Department of Laboratory Medicine, China Medical University Hospital; ¶Department of Nursing, Hungkuang University; **Epigenome Research Center and ††Department of Nuclear Medicine and PET Center, China Medical University Hospital; and ‡‡Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Abstract
PURPOSE: The aim of this study was to understand the association between various genetic mutation and (18)F-FDG PET-related parameters in patients with colorectal cancer (CRC). METHODS: One hundred three CRC patients who had undergone preoperative PET/CTs were included in this study. Several PET/CT-related parameters, including SUV(max), and various thresholds of metabolic tumor volume, total lesion glycolysis, and PET/CT-based tumor width (TW) were measured. Using high-resolution melting methods for genetic mutation analysis, tumor- and PET/CT-related parameters were correlated with various genetic alterations including TP53, KRAS, APC, BRAF, and PIK3CA. Mann-Whitney U test and logistic regression analysis were carried out for this analysis. RESULTS: Genetic alterations in TP53, KRAS, and APC were found in 41 (40%), 34 (33%), and 27 (26%) of tumors, respectively. PIK3CA and BRAF were exhibited by 5 and 4 of the patients with CRC. TP53 mutants exhibited higher SUV(max). The odds ratio was 1.28 (P = 0.04; 95% confidence interval, 1.01-1.61). Tumors with a mutated KRAS had an increased accumulation of FDG using a 40% threshold level for maximal uptake of TW (TW(40%)), whereas the odds ratio was 1.15 (P = 0.001; 95% confidence interval, 1.06-1.24). The accuracy of SUV(max) greater than 10 in predicting TP53 mutation was 60%, whereas that for TW(40%) for KRAS was 61%. CONCLUSIONS: Increased SUV(max) and TW(40%) were associated in CRC tumors with TP53 and KRAS mutations, respectively. Further studies are required because of the low predictive accuracy.
PURPOSE: The aim of this study was to understand the association between various genetic mutation and (18)F-FDG PET-related parameters in patients with colorectal cancer (CRC). METHODS: One hundred three CRC patients who had undergone preoperative PET/CTs were included in this study. Several PET/CT-related parameters, including SUV(max), and various thresholds of metabolic tumor volume, total lesion glycolysis, and PET/CT-based tumor width (TW) were measured. Using high-resolution melting methods for genetic mutation analysis, tumor- and PET/CT-related parameters were correlated with various genetic alterations including TP53, KRAS, APC, BRAF, and PIK3CA. Mann-Whitney U test and logistic regression analysis were carried out for this analysis. RESULTS: Genetic alterations in TP53, KRAS, and APC were found in 41 (40%), 34 (33%), and 27 (26%) of tumors, respectively. PIK3CA and BRAF were exhibited by 5 and 4 of the patients with CRC. TP53 mutants exhibited higher SUV(max). The odds ratio was 1.28 (P = 0.04; 95% confidence interval, 1.01-1.61). Tumors with a mutated KRAS had an increased accumulation of FDG using a 40% threshold level for maximal uptake of TW (TW(40%)), whereas the odds ratio was 1.15 (P = 0.001; 95% confidence interval, 1.06-1.24). The accuracy of SUV(max) greater than 10 in predicting TP53 mutation was 60%, whereas that for TW(40%) for KRAS was 61%. CONCLUSIONS: Increased SUV(max) and TW(40%) were associated in CRC tumors with TP53 and KRAS mutations, respectively. Further studies are required because of the low predictive accuracy.
Authors: Robin W Jansen; Paul van Amstel; Roland M Martens; Irsan E Kooi; Pieter Wesseling; Adrianus J de Langen; Catharina W Menke-Van der Houven van Oordt; Bernard H E Jansen; Annette C Moll; Josephine C Dorsman; Jonas A Castelijns; Pim de Graaf; Marcus C de Jong Journal: Oncotarget Date: 2018-04-13
Authors: E J van Helden; Y J L Vacher; W N van Wieringen; F H P van Velden; H M W Verheul; O S Hoekstra; R Boellaard; C W Menke-van der Houven van Oordt Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-09 Impact factor: 9.236
Authors: M Popovic; O Talarico; J van den Hoff; H Kunin; Z Zhang; D Lafontaine; S Dogan; J Leung; E Kaye; C Czmielewski; M E Mayerhoefer; P Zanzonico; R Yaeger; H Schöder; J L Humm; S B Solomon; C T Sofocleous; A S Kirov Journal: EJNMMI Res Date: 2020-11-23 Impact factor: 3.138
Authors: Felipe Montes de Jesus; V Vergote; W Noordzij; D Dierickx; R A J O Dierckx; A Diepstra; T Tousseyn; O Gheysens; T C Kwee; C M Deroose; A W J M Glaudemans Journal: J Clin Med Date: 2021-01-19 Impact factor: 4.241